

OMB#: 0925-0766, Exp., 04/2023

Burden Disclosure Statement: Public reporting burden for this collection of information is estimated to average 5 minut per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and person is not required to respond to, a collection of information unless it displays a currently valid OMB control number Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestifor reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648) Do not return the completed form to this address						
1. Is this your first time participating in a review meeting for NIH (not including service as a mail reviewer)?						
O No						
O Yes						
O Don't know						
2. Was your Fall 2022 review meeting held virtually or face-to-face?						
O Virtually						
O Face-to-face						
O Face-to face but I attended virtually						

3. Please select how mu	uch you agree	e or disagr	ree with the fo	ollowing sta	atements	5.			
	Strongly agree	Agree	Somewhat agree	Neutral		ewhat .gree	Disagı	ee Strongly disagree	
The panel was able to prioritize applications according to their impact and scientific merit.	0	0	0	0 0		0		0	
The scientific discussion helped the panel evaluate the applications being reviewed.	0	0	0	0		0		0	
4. Please rate your rece	ent review me	eting on th	ne following it		oor	Very p	oor	Don't know/Not	
Overall quality of								applicable	
review	O	O	O		0)	0	
Productivity of discussions	0	0	0		0	0		O	
Level of reviewer engagement	0	0	0	0		(0	
Meeting management	0	0	0		0	(0	
5. Please rate your rece	ent review me Always o very frequent	or Oft		ems. etimes	Rarely	٨	lever	Don't know/Not applicable	
I contributed to the discussion.	0		O	0	0		0	0	
I felt confident voicing my opinions.	3		0	0	0		0	0	
I felt others were receptive and responsive to my feedback.	0		0	0	0		0	0	
I was able to clearly communicate my opinions.	0		0	0	0		0	0	
I felt comfortable votin outside the range.	g O		O	0	0	0 0		0	

Rate your attention span at the review meetingbeing no problem concentrating at all.	fron	n 1-1	.0, w	ith 1	bein	ıg rea	ally s	strug	gled	to co	ncer	ntrate and
	1	2	3	4	5	6	6	7	8	9	1 0	
			_			-				!		
7. Did you experience any technical difficulties wi	th yo	our v	irtual	revi	ew n	neeti	ng (e	e.g. a	audic	, vis	ual, (connecting)?
O Yes												
O No												
O Don't know												
3. Assuming no or minimal health risks from COV meeting if it was held face-to-face or over video/Z			ould	you	be m	nore	likely	/ to p	oartic	ipate	e in a	ı review
O Face-to-face												
O Video/Zoom												
O No preference												

Approximately how many r	review me	eetings hav 1	e you participated 2-5	in for NIH? 6-15	16+
Face-to-face meetings	0	0	0	0	0
Virtual meetings	0	0	O	0	0
10. What stage of your caree	r are you	in?			
O Assistant Professor					
O Associate Professor					
O Professor					
O Other					
11. What is your sex?					
O Male					
O Female					
O I prefer not to respond	t				
12. Are you Hispanic or Latin	0?				
O Yes					
O No					
O I prefer not to respond	t				

13. Whic	ch racial group(s) do you primarily identify as? Select all that apply.
	American Indian or Alaska Native
	asian
П	Black or African-American
	lative Hawaiian or other Pacific Islander
Ov	Vhite
	prefer not to respond
1.4	nich II.C. timo zona da vou liva?
	nich U.S. time zone do you live? Eastern Time (ET)
0 0	Central Time (CT)
0	Mountain Time (MT)
O F	Pacific Time (PT)
0	Alaska Time (AT)
O F	ławaii-Aleutian Time (HAT)
0 0	Other U.S. time zone
O i	do not live in a U.S. time zone
	se share any comments (positive or negative) about your experience or general thoughts on your eview meeting.